GSK said on Friday that its respiratory syncytial virus (RSV) vaccine has received approval in Japan for expanded use in ...

British drugmaker GSK said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat ...

GlaxoSmithKline (GSK) has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for its regulatory ...

The US Food and Drug Administration (FDA) is expected to make a Prescription Drug User Fee Act (PDUFA) decision by mid-2025.

GSK (GSK) announced the US Food and Drug Administration, FDA, has accepted for review a Biologics License Application, BLA, for Blenrep in combinations with bortezomib plus dexamethasone and ...

GSK plc (GSK, GSK.L) announced that the US Food and Drug Administration has accepted for review a Biologics License Application (BLA) ...

Pharma titan GSK has announced that US regulators have accepted for review Blenrep combinations for the treatment of relapsed ...

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price an opportunity ...

US FDA accepts for review GSK’s Blenrep combinations for the treatment of relapsed/refractory multiple myeloma: London, UK Tuesday, November 26, 2024, 09:00 Hrs [IST] GSK plc an ...

The GSK share price has been in a strong freefall after peaking at 1,785p in September. Most recently, the GSK stock ...

A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to ...

GSK PLC said on Monday that the US Food & Drug Administration accepted a biologics license application for its Blenrep combinations for the treatment of relapsed and refractory multiple myeloma, both ...